ConductScience.org, home

Comparison · NCT01778634-75eff08e

Azithromycin vs Placebo (5% Dextrose): Number of Participants With Death or Neurodevelopmental Impairment

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Azithromycin vs Placebo (5% Dextrose): Number of Participants With Death or Neurodevelopmental Impairment. Trial comparisons, record NCT01778634-75eff08e. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01778634-75eff08e

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.4720.3440.603wilson
Risk in group 20.3270.2150.462wilson
Risk difference, group 1 minus group 20.145-0.04150.317newcombe hybrid score
Risk ratio, group 1 over group 21.440.892.34log
Odds ratio, group 1 over group 21.840.8334.06log
Number needed to treat, for one more participant with the outcome on Azithromycin than on Placebo (5% Dextrose)6.91from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1AzithromycinAzithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days~Azithromycin: Azithromycin intravenous 20 mg/kg every 24 h x 3 days2553OG001
Group 2Placebo (5% Dextrose)Placebo~Placebo: D5W 10 ml/kg every 24 h x 3 days1752OG000

Outcome

Type
SECONDARY
Title
Number of Participants With Death or Neurodevelopmental Impairment
Description
Neurodevelopmental impairment will be assigned if any of the following are present at 22-26 months adjusted age: moderate to severe cerebral palsy, bilateral blindness, bilateral hearing impairment requiring amplification, Gross Motor Function Classification System score ≥ 2, or Bayley Scale of Infant and Toddler Development, 3rd edition (BSID-III) cognitive or motor score \<70.
Time frame
22-26 months
Population
Participants who died prior to the 22-26 months assessment timepoint and participants who were assessed for neurodevelopmental impairments

Source ClinicalTrials.gov

Trial

Title
Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants
NCT number
NCT01778634
Phases
PHASE2
Conditions
Ureaplasma Infections
Interventions
Azithromycin, Placebo
Lead sponsor
University of Maryland, Baltimore
Results first posted
2018-05-17

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01778634-75eff08e